NeuroEndocrine Tumours Clinical Trial
Official title:
A Phase IV, Multicentre, Open Label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients Receiving Deep Subcutaneous Administrations of Somatuline® (Lanreotide) Autogel® to Treat the Symptoms of Functioning Midgut NeuroEndocrine Tumours (NET)
Circulating tumour cells (CTCs) are detectable in the blood in around 50% of patients with
functioning NeuroEndocrine Tumours (NET) arising in the midgut area (tumours which are
secreting hormones and are located in the area in the middle of the digestive system) and
their presence usually means that the prognosis for the patient is poor. CTCs have also been
shown to be valuable as predictive markers following treatment and there is increasing
interest in using CTCs as 'liquid biopsies' that can help to inform treatment decisions. CTC
analysis has the benefit of being relatively non- invasive and quick compared with a
conventional CT scan and is therefore an attractive method of monitoring the tumour
throughout the treatment period.
The purpose of this study is to assess the clinical value that enumeration will have in
predicting the clinical symptomatic response and progression free survival in patients
receiving Somatuline Autogel for functioning midgut NETs over a one year period.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00323076 -
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
|
Phase 1/Phase 2 | |
| Completed |
NCT00326469 -
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
|
Phase 2 | |
| Terminated |
NCT02788578 -
A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours
|
||
| Completed |
NCT01840449 -
Somatuline Predictive Factors in Acromegaly and NET
|
||
| Completed |
NCT02698410 -
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
|
Phase 2 | |
| Active, not recruiting |
NCT02923934 -
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
|
Phase 2 | |
| Completed |
NCT01673906 -
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
|
Phase 2 | |
| Active, not recruiting |
NCT04579679 -
Open-Label Surufatinib in European Patients With NET
|
Phase 2 |